What Happened
- In January 2026, India's IHR National Focal Point notified WHO of two confirmed Nipah virus (NiV) infections in West Bengal, with laboratory confirmation from the National Institute of Virology (NIV), Pune on 13 January 2026.
- WHO issued a disease outbreak notice and conducted an expert perspectives webinar through its South-East Asia Regional Office (SEARO) in February 2026.
- WHO assessed the risk as moderate at the sub-national level, and low at the national, regional, and global levels, ruling out widespread transmission.
- No licensed vaccine or specific antiviral treatment exists for Nipah virus infection.
- Since 2018, Kerala alone has reported nine NiV outbreaks; the 2025 Kerala outbreak (May-July) recorded four cases including two deaths.
Static Topic Bridges
Nipah Virus: Virology, Transmission and Clinical Features
Nipah virus (NiV) belongs to the genus Henipavirus within the family Paramyxoviridae. Its natural reservoir is fruit bats (flying foxes) of the genus Pteropus, which are widely distributed across South and Southeast Asia and Oceania. Transmission to humans occurs via direct contact with infected bats or their secretions (date palm sap contamination is a key route in Bangladesh), through infected pigs or other intermediate hosts, and via limited human-to-human transmission among close contacts. Clinical presentation ranges from asymptomatic infection to acute respiratory illness and fatal encephalitis (brain inflammation). The case fatality ratio ranges from 40% to 75% across different outbreaks.
- Family: Paramyxoviridae; Genus: Henipavirus
- Natural reservoir: Pteropus fruit bats (flying foxes)
- Transmission: Bat→human (via food/contact), animal→human, limited human→human
- CFR: 40–75% depending on healthcare capacity and early detection
- Clinical features: fever, headache, encephalitis, respiratory distress
- First identified: 1999 in Nipah village, Malaysia (in pig farmers)
- No licensed vaccine or specific treatment (ribavirin used off-label)
Connection to this news: The 2026 West Bengal cases follow the same epidemiological pattern as previous Indian outbreaks — bat-associated zoonotic spillover with limited human-to-human spread — which is why WHO assessed global risk as low despite the high CFR of the virus.
India's Zoonotic Disease Surveillance and One Health Approach
India's repeated Nipah outbreaks (Kerala 2018, 2021, 2023; West Bengal 2024, 2026) have underscored the importance of the One Health framework — an integrated approach recognising that human, animal, and environmental health are interconnected. The National Centre for Disease Control (NCDC) under the Ministry of Health and Family Welfare coordinates outbreak surveillance, while the National Institute of Virology (NIV), Pune (under ICMR) serves as the apex reference laboratory for rare viral pathogens. India's Integrated Disease Surveillance Programme (IDSP) provides district-level sentinel surveillance.
- One Health: WHO-FAO-OIE tripartite framework, endorsed in India's National Health Policy 2017
- NCDC: National apex body for disease surveillance (under MoHFW)
- NIV Pune: ICMR institute; confirmed NiV in 2026 West Bengal cases
- IDSP: Integrated Disease Surveillance Programme — India's primary outbreak detection network
- Kerala containment model (2018): Rapid contact tracing, quarantine of 2,500+ contacts, geographic ring containment — internationally praised
- IHR (International Health Regulations) 2005: Mandates state parties to notify WHO of events of potential international public health concern (PHEIC threshold)
Connection to this news: India notified WHO through IHR NFP channels — demonstrating compliance with IHR 2005 obligations. The swift lab confirmation (NIV Pune) and WHO risk assessment demonstrate the strengthened surveillance architecture built after the 2018 Kerala experience.
WHO's Role in Epidemic Preparedness: R&D Blueprint and CEPI
WHO's R&D Blueprint for Action to Prevent Epidemics identifies Nipah virus as a priority pathogen warranting urgent research and development, alongside Ebola, Marburg, MERS-CoV, and others, due to its epidemic potential and lack of medical countermeasures. The Coalition for Epidemic Preparedness Innovations (CEPI) is funding NiV vaccine development, with candidates in clinical trials. Nipah does not yet qualify as a Public Health Emergency of International Concern (PHEIC) under IHR 2005 as outbreak clusters remain localised.
- WHO R&D Blueprint Priority Pathogens: Nipah listed alongside Ebola, MERS-CoV, SARS, Disease X
- CEPI: Public-private global initiative for epidemic vaccine development; India is a key donor
- PHEIC (Public Health Emergency of International Concern): Highest WHO alert level — not declared for Nipah outbreaks to date
- Monoclonal antibody m102.4: Experimental treatment showing promise in animal models
- Global distribution of Pteropus bats extends Nipah spillover risk to Southeast Asia, Bangladesh, India
Connection to this news: WHO's 2026 warning reflects its Blueprint mandate to proactively communicate risks even when global spread is unlikely — maintaining vigilance given Nipah's high CFR and pandemic potential if it gains efficient human-to-human transmission.
Key Facts & Data
- Virus family: Paramyxoviridae; Genus: Henipavirus
- Natural reservoir: Pteropus fruit bats
- CFR: 40–75% (varies by outbreak and healthcare capacity)
- First identified: 1999, Nipah village, Malaysia
- India's NiV outbreaks: Kerala (2018, 2019, 2021, 2023, 2025), West Bengal (2001, 2007, 2024, 2026)
- 2026 outbreak: 2 confirmed cases, West Bengal; confirmed by NIV Pune (Jan 2026)
- WHO risk assessment (2026): Moderate sub-nationally, Low nationally/globally
- No licensed vaccine or treatment available
- Lab confirmation agency in India: NIV, Pune (under ICMR)
- Surveillance framework: IDSP (district level), NCDC (national apex), IHR NFP (WHO notification)